Expression cloning of a new member of the ABO blood group glycosyltransferases, iGb3 synthase, that directs the synthesis of isoglobo-glycosphingolipids.

The large array of different glycolipids described in mammalian tissues is a reflection, in part, of diverse glycosyltransferase expression. Herein, we describe the cloning of a UDP-galactose: beta-d-galactosyl-1,4-glucosylceramide alpha-1, 3-galactosyltransferase (iGb(3) synthase) from a rat placental cDNA expression library. iGb(3) synthase acts on lactosylceramide, LacCer (Galbeta1,4Glcbeta1Cer) to form iGb(3) (Galalpha1,3Galbeta1, 4Glcbeta1Cer) initiating the synthesis of the isoglobo-series of glycosphingolipids. The isolated cDNA encoded a predicted protein of 339 amino acids, which shows extensive homology (40-50% identity) to members of the ABO gene family that includes: murine alpha1, 3-galactosyltransferase, Forssman (Gb(5)) synthase, and the ABO glycosyltransferases. In contrast to the murine alpha1, 3-galactosyltransferase, iGb(3) synthase preferentially modifies glycolipids over glycoprotein substrates. Reverse transcriptase-polymerase chain reaction revealed a widespread tissue distribution of iGb(3) synthase RNA expression, with high levels observed in spleen, thymus, and skeletal muscle. As an indirect consequence of the expression cloning strategy used, we have been able to identify several potential glycolipid biosynthetic pathways where iGb(3) functions, including the globo- and isoglobo-series of glycolipids.

Cloning of Gb3 synthase, the key enzyme in globo-series glycosphingolipid synthesis, predicts a family of alpha 1, 4-glycosyltransferases conserved in plants, insects, and mammals.

We have cloned Gb(3) synthase, the key alpha1, 4-galactosyltransferase in globo-series glycosphingolipid (GSL) synthesis, via a phenotypic screen, which previously yielded iGb(3) synthase, the alpha1,3-galactosyltransferase required in isoglobo-series GSL (Keusch, J. J., Manzella, S. M., Nyame, K. A., Cummings, R. D., and Baenziger, J. U. (2000) J. Biol. Chem. 33). Both transferases act on lactosylceramide, Galbeta1,4Glcbeta1Cer (LacCer), to produce Gb(3) (Galalpha1,4LacCer) or iGb(3) (Galalpha1, 3LacCer), respectively. GalNAc can be added sequentially to either Gb(3) or iGb(3) yielding globoside and Forssman from Gb(3), and isogloboside and isoForssman from iGb(3). Gb(3) synthase is not homologous to iGb(3) synthase but shows 43% identity to a human alpha1,4GlcNAc transferase that transfers a UDP-sugar in an alpha1, 4-linkage to a beta-linked Gal found in mucin. Extensive homology (35% identity) is also present between Gb(3) synthase and genes in Drosophila melanogaster and Arabidopsis thaliana, supporting conserved expression of an alpha1,4-glycosyltransferase, possibly Gb(3) synthase, throughout evolution. The isolated Gb(3) synthase cDNA encodes a type II transmembrane glycosyltransferase of 360 amino acids. The highest tissue expression of Gb(3) synthase RNA is found in the kidney, mesenteric lymph node, spleen, and brain. Gb(3) glycolipid, also called P(k) antigen or CD77, is a known receptor for verotoxins. CHO cells that do not express Gb(3) and are resistant to verotoxin become susceptible to the toxin following transfection with Gb(3) synthase cDNA.

Establishment of stroke treatment plans: one hospital's experience.

Stroke remains one of the major causes of death and permanent disability in the United States, ranking as the third leading cause of death behind heart disease and cancer. It affects an estimated 700,000 persons each year; about two-thirds of those with a new or recurrent stroke survive. The aggregate cost of stroke in the United States is more than $40 billion per year, with an average cost per case of approximately $50,000. With the advent of recombinant tissue-type plasminogen activator (t-PA) for acute stroke, clinical pathways have been developed to provide efficient care to acute stroke patients. Efforts must be aimed at educating the public and all members of the healthcare team about proper stroke care. Surprisingly, only 20%-30% of all hospitals have stroke teams in place. To bring stroke care into the 21st century, this deficiency must be addressed and additional treatment agents such as neuroprotective medications need to be approved.

Complementary healthcare practices and the implications for nurse practitioners.

Complementary, or alternative, healthcare practices are being incorporated into approximately 4 out of 10 Americans' daily health practices. The out-of-pocket expense for such healthcare use was estimated at $21.2 billion in 1997. There are many different forms of complementary health care that nurse practitioners (NPs) must be aware of when evaluating and forming plans of care with their patients. NPs must develop and incorporate interview techniques to obtain this information from their patients to prevent potential interactions. NPs must also be aware of their lack of experience with complementary healthcare practices and the legal liability of incorporating these practices into their practice without appropriate preparation in their use.

Tissue plasminogen activator for acute stroke in everyday clinical practice.

Thrombolysis for acute ischemic stroke has become a reality. The aim of our study was to assess the opportunity and practicality of establishing acute stroke treatment in a hospital that did not participate in acute stroke treatment trials, as well as to prospectively analyze 2 groups of patients who reached the Emergency Department (ED) within 3 hours who were either treated or not treated with tissue plasminogen activator (t-PA). The average score for severity of neurological deficits for the patients who received t-PA was 14 on the National Institute of Health Stroke Scale (NIHSS). We compare this group with 18 patients who did not receive t-PA but had similar NIHSS scores (13.9 average). Both groups were matched for age and other comorbidity factors. We concluded that the establishment of an acute stroke treatment algorithm is possible de novo in a hospital that is equipped with computed tomography (CT) and neurosurgery services. The number of patients who can receive t-PA treatment is limited by the strict inclusion and exclusion criteria. Prolonged door-to-needle time was caused by delays in CT interpretation, processing of laboratory results, and stabilization of blood pressure. Patients who received t-PA had a shorter length of stay, were more independent, and had a better survival rate after 1 year. Our findings were in agreement with the National Institute of Neurological Disorders and Stroke (NINDS) Stroke Study that led to the approval of the use of t-PA in the treatment of acute ischemic stroke.

Developmental regulation of a pregnancy-specific oligosaccharide structure, NeuAcalpha2,6GalNAcbeta1,4GlcNAc, on select members of the rat placental prolactin family.

Successful pregnancy is dependent upon an array of signaling proteins secreted by the trophoblast cells of the placenta. Among these is a group of proteins related to pituitary prolactin, known as the prolactin/growth hormone family. These proteins are expressed at specific times during gestation and synthesized in distinct trophoblast cell types in the rat placenta. We report here that select members of this family, prolactin-like protein (PLP-A), PLP-B, PLP-C, decidual/trophoblast PRP, and placental lactogen I variant, only which are expressed in the spongiotrophoblast, late in rat placental development bear Asn-linked oligosaccharides terminating with NeuAcalpha2,6GalNAcbeta1,4GlcNAcbeta-R. This reflects the concurrent expression of these prolactin/growth hormone family members with the peptide-specific beta1,4GalNAc-transferase and an alpha2,6-sialyltransferase, which can add sialic acid to terminal beta1,4-linked GalNAc. We have determined that at least one of the prolactin-like proteins, PLP-A, is recognized by the protein-specific GalNAc-transferase. The presence of NeuAcalpha2, 6GalNAcbeta1,4GlcNAcbeta-R on only a limited number of glycoproteins synthesized by the spongiotrophoblasts between mid gestation and birth reflects the need for both the GalNAc-transferase and the peptide recognition determinant for efficient addition of GalNAc. Thus, expression of the GalNAc-transferase and specific members of the prolactin/growth hormone family is developmentally regulated in the rat placenta, suggesting a physiological role for the terminal NeuAcalpha2,6GalNAcbeta1,4GlcNAcbeta-R sequence on Asn-linked oligosaccharides of these proteins.

From legumes to leukocytes: biological roles for sulfated carbohydrates.

Carbohydrates attached to proteins and lipids characteristically display complex and heterogeneous structures. However, it is becoming increasingly clear that carbohydrates with definite biological functions also exhibit unique structural features. A number of glycoproteins and glycolipids have been shown to bear oligosaccharides containing sulfate. Often, addition of a sulfate moiety turns a relatively common structural motif into a unique carbohydrate with the potential to be recognized by a specific receptor or lectin. This is clearly the case in three systems in which sulfated oligosaccharides have been shown to play a well-defined biological role: 1) control of the circulatory half-life of luteinizing hormone, 2) symbiotic interactions between leguminous plants and nitrogen-fixing bacteria, and 3) homing of lymphocytes to lymph nodes. The rapidly growing list of glycoproteins and glycolipids identified as bearing sulfated oligosaccharides suggests that sulfated carbohydrates play important biological roles in numerous other systems as well.-Hooper, L. V., Manzella, S. M., Baenziger, J. U. From legumes to leukocytes: biological roles for sulfated carbohydrates.

Evolutionary conservation of the sulfated oligosaccharides on vertebrate glycoprotein hormones that control circulatory half-life.

The circulatory half-life of the mammalian glycoprotein hormone lutropin is controlled by its unique Asn-linked oligosaccharides, which terminate with the sequence SO4-4-GalNAc beta 1,4GlcNAc. A cluster of basic amino acids essential for recognition of the alpha subunit by the glycoprotein hormone:N-acetylgalactosaminyltransferase is located within two turns of an alpha helix (Mengeling, B.J., Manzella, S.M., and Baenziger, J.U. (1995) Proc. Natl. Acad. Sci. U.S.A. 92, 502-506). The amino acids within this region are virtually invariant in the alpha subunits of all vertebrates, indicating that the recognition determinant utilized by the N-acetylgalactosaminyltransferase has been conserved in species ranging from teleost fish to mammals. We demonstrate that the glycoprotein hormone:N-acetylgalactosaminyltransferase and the N-acetylgalactosamine-4-sulfotransferase responsible for the synthesis of these unique sulfated oligosaccharides are expressed in the pituitaries of vertebrates ranging from teleost fish to mammals. Furthermore, we show that Asn-linked oligosaccharides terminating with SO4-4-GalNAc beta 1,4GlcNAc are present on the alpha and beta subunits of the salmon glycoprotein hormone GTH II. Asn-linked oligosaccharides terminating with SO4-4-GalNAc beta 1,4GlcNAc are unique structural features of the glycoprotein hormones that have been conserved during vertebrate evolution, suggesting they are critical for the expression of hormone biologic activity.

Differential expression of GalNAc-4-sulfotransferase and GalNAc-transferase results in distinct glycoforms of carbonic anhydrase VI in parotid and submaxillary glands.

Differential expression of glycosyltransferases has the potential to generate functionally distinct glycoforms of otherwise identical proteins. We have previously demonstrated the presence of unique oligosaccharides terminating with GalNAc-4-SO4 on the pituitary glycoproteins lutropin (LH), thyroid stimulating hormone (TSH), and pro-opiomelanocortin (POMC). A glycoprotein hormone:GalNAc-transferase and a GalNAc-4-sulfotransferase are present in the pituitary and can account for the synthesis of these unique oligosaccharides on specific glycoproteins. Both transferases are coordinately expressed in a number of tissues in addition to pituitary, including submaxillary gland, lacrimal gland, and kidney, suggesting that additional glycoproteins bearing oligosaccharides terminating with GalNAc-4-SO4 are synthesized in these tissues. In this study we show that while the glycoprotein hormone:GalNAc-transferase and the GalNAc-4-sulfotransferase are coordinately expressed in bovine submaxillary gland, the GalNAc-transferase is expressed in the parotid gland in the absence of the GalNAc-4-sulfotransferase. The relative expression of these two transferases in submaxillary and parotid glands correlates with the presence of unique Asn-linked oligosaccharides on carbonic anhydrase VI (CA VI) synthesized in each of these tissues. The majority of Asn-linked oligosaccharides on CA VI synthesized in submaxillary gland terminate with GalNAc-4-SO4. In contrast, CA VI which is synthesized in bovine parotid gland bears oligosaccharides which terminate predominantly with beta 1,4-linked GalNAc which is not sulfated. The presence of different terminal residues on the Asn-linked oligosaccharides of submaxillary and parotid CA VI thus correlates with the complement of transferases in these glands and suggests differing biological roles for submaxillary and parotid CA VI.

Dodecyl-beta-D-maltoside as a substrate for glucosyl and xylosyl transfer by glycogenin.

Glycogenin is the core protein of glycogen proteoglycan and is, at the same time, a self-glucosylating enzyme which catalyses early glucosyl transfer steps in the biosynthesis of glycogen. In the course of this process, glycogenin is glucosylated progressively until an oligosaccharide containing 8-11 glucose residues has been formed. Although glycogenin, under physiological conditions, is both enzyme and acceptor in the glucosyl transfer reactions, it is also capable of utilizing p-nitrophenyl-linked malto-oligosaccharides as exogenous acceptors. In view of the potential usefulness of exogenous acceptors in the study of the mechanism of the glycogenin reaction, we have expanded the search for such compounds and report here that several alkyl glucosides and alkyl maltosides may serve as acceptors in glucosyl transfer by beef kidney glycogenin. Dodecyl-beta-D-maltoside (Km approximately 100 microM) was the most effective acceptor among the compounds tested and yielded 30 times as much product as p-nitrophenyl-alpha-maltoside. Substantial product formation was also observed with tetradecyl-beta-D-maltoside and octyl-beta-D-maltoside (39 and 22%, respectively, of the value measured for dodecyl-beta-D-maltoside). It was further demonstrated that dodecyl-beta-D-maltoside served as an acceptor in the transfer of xylose from UDP-xylose, indicating that the exogenous substrate behaved similarly to glycogenin itself in this regard. Dodecyl-beta-D-maltoside has already proven useful in the development of a simple glycogenin assay, and it is further suggested that this and related compounds may be active in vivo and in cell culture as artificial initiators of glycogen synthesis.

A cluster of basic amino acids within an alpha-helix is essential for alpha-subunit recognition by the glycoprotein hormone N-acetylgalactosaminyltransferase.

The glycoprotein hormone N-acetylgalactosaminyltransferase is responsible for synthesis of Asn-linked oligosaccharides terminating with GalNAc-4-SO4 on lutropin, thyrotropin, and the uncombined glycoprotein hormone alpha subunit. We previously established that a recognition determinant for the N-acetylgalactosaminyltransferase is contained within a 22-amino acid glycopeptide fragment of the alpha subunit. We proposed that the tripeptide Pro-Leu-Arg is an essential element of the recognition determinant. Using site-directed mutagenesis we have examined the role of individual amino acids in recognition by the glycoprotein hormone N-acetylgalactosaminyltransferase. Within the sequence Pro40-Leu41-Arg42-Ser43-Lys44-Lys45, Lys44, and Lys45, as well as Arg42 of the tripeptide, are essential for recognition. Substitution of the Leu41 with other amino acids can either increase or decrease the rate of GalNAc transfer over an 8-fold range, suggesting that the middle amino acid of the tripeptide plays a modulatory role in recognition. The critical Leu41-Arg42 and Lys44-Lys45 residues are present on the same surface of an alpha-helix, which projects from the surface of the alpha subunit. Our results indicate that an essential element of the recognition determinant consists of a cluster of basic residues and that neutral but not negatively charged residues are tolerated within this cluster.

A biphasic radiometric assay of glycogenin using the hydrophobic acceptor n-dodecyl-beta-D-maltoside.

Glycogenin is a self-glycosylating protein that catalyzes early glucosyl transfer steps in the biosynthesis of glycogen. In currently used assays of glycogenin activity, the enzyme is incubated with radioactive UDP-glucose, and the labeled reaction product is then isolated by precipitation with trichloroacetic acid. A new assay is reported here which is based on the observation that glycogenin is not only self-glycosylating but may also use exogenous alkyl maltosides as substrates. After incubation of the enzyme with n-dodecyl-beta-D-maltoside and UDP-[3H]glucose, the radioactivity in the resultant n-dodecyl-beta-D-[3H]maltotrioside is determined by any one of the following three procedures, which all rely on the hydrophobic properties conferred on the reaction product by the alkyl aglycone: (i) adsorption of the product to a Sep-Pak C18 cartridge and elution with 70% ethanol; (ii) biphasic liquid scintillation counting in ScintiLene/25% isoamyl alcohol, without isolation of the product, and (iii) precipitation with trichloroacetic acid in the presence of carrier protein. The Sep-Pak C18 procedure has the advantage that it allows essentially quantitative isolation of the reaction product, while, under the conditions chosen, only about 50% of the product is precipitated by trichloroacetic acid. For most applications, however, biphasic liquid scintillation counting is the method of choice, since close to 90% of the labeled product is extracted into the organic phase and can be counted directly without interference from the labeled nucleotide sugar which remains in the aqueous phase.(ABSTRACT TRUNCATED AT 250 WORDS)